Cargando…

Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?

Recent data suggest that obsessive-compulsive disorder (OCD) is driven by an imbalance among the habit learning system and the goal-directed system. The frontostriatal loop termed cortico-striatal-thalamo-cortical (CSTC) circuitry loop is involved in habits and their dysfunction plays an important r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maraone, Annalisa, Tarsitani, Lorenzo, Pinucci, Irene, Pasquini, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474998/ https://www.ncbi.nlm.nih.gov/pubmed/34631461 http://dx.doi.org/10.5498/wjp.v11.i9.568

Ejemplares similares

Psychic euosmia and obsessive compulsive personality disorder
por: Pasquini, Massimo, et al.
Publicado: (2018)

Insomnia among Cancer Patients in the Real World: Optimising Treatments and Tailored Therapies
por: Pinucci, Irene, et al.
Publicado: (2023)

Schema Therapy and Obsessive-Compulsive Disorder
por: Pasquini, Massimo, et al.
Publicado: (2022)

Psychic euosmia among obsessive-compulsive personality disorder patients: A case control study
por: Maraone, Annalisa, et al.
Publicado: (2021)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review
por: Piacentino, Daria, et al.
Publicado: (2020)

Role of endoscopic ultrasound in vascular interventions: Where are we now?
por: Fugazza, Alessandro, et al.
Publicado: (2022)

Esophagogastric junction outflow obstruction: Where are we now in diagnosis and management?
por: Samo, Salih, et al.
Publicado: (2019)

Viscoelastic tests in liver disease: where do we stand now?
por: Buliarca, Alina, et al.
Publicado: (2021)

Second-line rescue treatment of Helicobacter pylori infection: Where are we now?
por: Lin, Te-Fu, et al.
Publicado: (2018)

Circulating tumor DNA: Where are we now? A mini review of the literature
por: Galarza Fortuna, Gliceida Maria, et al.
Publicado: (2020)

Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial
por: Maraone, Annalisa, et al.
Publicado: (2023)

A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder
por: Accinni, Tommaso, et al.
Publicado: (2022)

Apical polarity in three-dimensional culture systems: where to now?
por: Inman, Jamie L, et al.
Publicado: (2010)

Obsessive-Compulsive Disorder and suicide: what do we know up until now?
por: Salvadori, G., et al.
Publicado: (2022)

Artificial intelligence and inflammatory bowel disease: Where are we going?
por: Da Rio, Leonardo, et al.
Publicado: (2023)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Where are we now?
Publicado: (1977)

Sessile serrated adenoma/polyps: Where are we at in 2016?
por: Singh, Rajvinder, et al.
Publicado: (2016)

Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019)

Defining the Pseudomonas Genus: Where Do We Draw the Line with Azotobacter?
por: Özen, Asli I., et al.
Publicado: (2011)

Hepatitis C virus micro-elimination: Where do we stand?
por: Mangia, Alessandra, et al.
Publicado: (2021)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

Role of endoscopic ultrasound in liver disease: Where do we stand in 2017?
por: Saraireh, Hamzeh A, et al.
Publicado: (2017)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

Aripiprazole Augmentation in Patients with Resistant Obsessive Compulsive Disorder: a Pilot Study
por: Delle Chiaie, Roberto, et al.
Publicado: (2011)

Editorial: Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders
por: Pasquini, Massimo, et al.
Publicado: (2020)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Platelet-Rich Plasma: Where Are We Now and Where Are We Going?
por: Cole, Brian J., et al.
Publicado: (2010)

Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Ten Years for GHSP: Where Are We Now? Where Will We Go?
por: Bhutta, Zulfiqar A., et al.
Publicado: (2023)

Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023)

CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)

Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?
por: Galanopoulos, Michail, et al.
Publicado: (2018)

Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2021)

Monkeypox and Its Possible Sexual Transmission: Where Are We Now with Its Evidence?
por: Sah, Ranjit, et al.
Publicado: (2022)

Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going
por: Mazzitelli, Carlotta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7217uuqfstrkii1rkkoihrmig1